• Safety First: Veritone (VERI) Provides Intelligence Platform to Universities, School Campuses and Public Safety Agencies
    • Evolution Petroleum Releases Fourth Quarter Results and Leads PRISM Oil and Gas Index
    • OS Therapies (OSTX) Releases Positive Efficacy and Safety Data for Ovarian Cancer Therapeutic Candidate Utilizing Tunable Antibody Drug Conjugate (tADC) Platform
    Safety First: Veritone (VERI) Provides Intelligence Platform to Universities, School Campuses and Public Safety Agencies
    PRISM View

    Safety First: Veritone (VERI) Provides Intelligence Platform to Universities, School Campuses and Public Safety Agencies

    New York, September 12, 2024 - PRISM MarketView - PRISM AdTech and Media Index Veritone (VERI) who is a leader in developing human-centered enterprise AI solutions, has announced the launch of its intelligent digital evidence management system, Veritone iDEMS. This syste...
    Evolution Petroleum Releases Fourth Quarter Results and Leads PRISM Oil and Gas Index
    PRISM View

    Evolution Petroleum Releases Fourth Quarter Results and Leads PRISM Oil and Gas Index

    New York, September 11, 2024 - PRISM MarketView - The PRISM Oil and Gas Index company Evolution Petroleum (EPM) has released its fourth quarter financial results. Overall, the report disappointed on most earnings metrics falling short of consensus. EPS was reported at $0...
    OS Therapies (OSTX) Releases Positive Efficacy and Safety Data for Ovarian Cancer Therapeutic Candidate Utilizing Tunable Antibody Drug Conjugate (tADC) Platform
    PRISM Biotech

    OS Therapies (OSTX) Releases Positive Efficacy and Safety Data for Ovarian Cancer Therapeutic Candidate Utilizing Tunable Antibody Drug Conjugate (tADC) Platform

    New York, September 11, 2024 - PRISM MarketView - The clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, OS Therapies (OSTX) today announced positive data in animal models of ovarian cancer for its first therapeutic candidate developed ba...
    Safety First: Veritone (VERI) Provides Intelligence Platform to Universities, School Campuses and Public Safety Agencies
    Evolution Petroleum Releases Fourth Quarter Results and Leads PRISM Oil and Gas Index
    OS Therapies (OSTX) Releases Positive Efficacy and Safety Data for Ovarian Cancer Therapeutic Candidate Utilizing Tunable Antibody Drug Conjugate (tADC) Platform
    PRISM View
    Safety First: Veritone (VERI) Provides Intelligence Platform to Universities, School Campuses and Public Safety Agencies

    New York, September 12, 2024 - PRISM MarketView - PRISM AdTech and Media Index Veritone (VERI) who is a leader in developing human-centered enterprise AI solutions, has announced the launch of its intelligent digital evidence management system, Veritone iDEMS. This syste...

    12 September 2024

    PRISM View
    Evolution Petroleum Releases Fourth Quarter Results and Leads PRISM Oil and Gas Index

    New York, September 11, 2024 - PRISM MarketView - The PRISM Oil and Gas Index company Evolution Petroleum (EPM) has released its fourth quarter financial results. Overall, the report disappointed on most earnings metrics falling short of consensus. EPS was reported at $0...

    11 September 2024

    PRISM Biotech
    OS Therapies (OSTX) Releases Positive Efficacy and Safety Data for Ovarian Cancer Therapeutic Candidate Utilizing Tunable Antibody Drug Conjugate (tADC) Platform

    New York, September 11, 2024 - PRISM MarketView - The clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, OS Therapies (OSTX) today announced positive data in animal models of ovarian cancer for its first therapeutic candidate developed ba...

    11 September 2024

    PRISM Biotech
    Terns Pharmaceuticals Announces Public Offering Following Positive Data on Weight-Loss Drug

    New York, September 11, 2024 - PRISM MarketView - Terns Pharmaceuticals (Nasdaq: TERN) has announced an upsized public offering of 11.9 million shares of common stock at $10.50 per share, with expected gross proceeds of approximately $150.15 million. This announcement fo...

    11 September 2024

    PRISM Biotech
    New Tilray Medical Study on Medical Cannabis Highlights Reduced Pain and Improved Sleep for Fibromyalgia Patients

    New York, September 10, 2024 - PRISM MarketView - Tilray Medical, a division of Tilray Brands, Inc. (Nasdaq: TLRY) and a leading global player in the medical cannabis sector, recently released a new study, “Treatment in Pain Management and Other Fibromyalgia-Associated S...

    10 September 2024

    PRISM Biotech
    Aclarion Technology Advances Global Validation with First Nociscan Exams in LIFEHAB Trial on Low Back Pain

    New York, September 10, 2024 - PRISM MarketView - Aclarion, Inc. (Nasdaq: ACON), a healthcare technology company focused on leveraging biomarkers and augmented intelligence to identify chronic low back pain, announced the completion of the first exams in its ongoing LIFE...

    10 September 2024

    News
    Aclarion Added to PRISM Emerging Medical Devices Index

    · Company's industry-first technology addresses chronic low back pain

    6 September 2024

    PRISM Biotech
    Lisata Therapeutics Secures FDA Orphan Drug Designation for Certepetide in Treating Aggressive Bile Duct Cancer

    New York, September 06, 2024 - PRISM MarketView - Lisata Therapeutics, Inc. (Nasdaq: LSTA), a clinical-stage pharmaceutical company developing therapies for advanced solid tumors, has announced that its investigational drug, certepetide, has been granted Orphan Drug Desi...

    6 September 2024

    PRISM View
    Aclarion Inc. (ACON) Launches Statewide Initiative to Deliver Advanced Personal Injury and Workers Compensation Diagnostics with AI Technology

    New York, September 05, 2024 - PRISM MarketView - Aclarion, Inc. (Nasdaq: ACON), a healthcare technology company utilizing biomarkers and AI algorithms to improve the diagnosis of chronic low back pain, announced a new partnership aimed at applying its Nociscan technolog...

    5 September 2024

    PRISM Biotech
    Veru Inc. (VERU) Advances Muscle Preservation Research with Enobosarm and Strengthens Financial Position

    New York, September 03, 2024 - PRISM MarketView - PRISM Emerging Weight Loss Index mover Veru Inc. (NASDAQ: VERU), is actively advancing its research and development efforts, particularly in its Phase 2b QUALITY clinical study for enobosarm—a drug designed to preserve mu...

    4 September 2024

    Social Media
    Press Kit

    See More

    PRISM Emerging Biotech Index

    PRISM Emerging Cannabis

    PRISM Emerging Consumer Products

    PRISM Emerging EV

    PRISM MarketView

    Founded in 2020, PRISM MarketView focuses on providing analysis and monitoring of small cap stocks in emerging sectors. PRISM MarketView offers current financial market news and commentary alongside a range of tools for investors. We specialize in creating and managing proprietary indexes that track sectors such as biotech, oil and gas, new energy, medical devices and more. 

    Our mission is to provide information and insights to empower investors in making informed decisions. Through PRISM MarketView, investors have access to the latest news and data, helping them stay informed about market trends and opportunities. 

    Join us in exploring the dynamic world of investing!


    We use cookies to run our website, analyze your use of our services, manage your online preference & personalize ad content. By accepting our cookies, you’ll get relevant content and social media features, personalized ads, and an enhanced browsing experience. To manage your choices, click „Cookie Settings”. Necessary cookies are required for the core website functionality and cannot be rejected. For more information, see our Cookie Policy.
    Cookie settings
    Cookies used on the site are categorized and below you can read about each category and allow or deny some or all of them, except for Necessary Cookies which are required to provide core website functionality. When categories that have been previously allowed are disabled, all cookies assigned to that category will be removed from your browser. You can see a list of cookies assigned to each category and detailed information on those cookies in the “Cookie Policy” tab.
    Necessary cookies
    Some cookies are required to provide core functionality. The website won't function properly without these cookies and they are enabled by default and cannot be disabled.
    Preferences
    Preference cookies enables the website to remember information to customize how the website looks or behaves for each user. This may include storing selected currency region, language or color theme.
    Analytical cookies
    Analytical cookies help us improve our website by collecting and reporting information on its usage.
    Marketing cookies
    Marketing cookies are used to track visitors across websites to allow publishers to display relevant and engaging advertisements. By enabling marketing cookies, you grant permission for personalized advertising across various platforms.